James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

Shares of UTHR opened at $532.53 on Friday. The business has a 50-day moving average of $494.79 and a 200 day moving average of $471.76. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $549.50. The firm has a market cap of $23.34 billion, a P/E ratio of 19.09, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $6.19 EPS. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support: Several brokerages have raised targets or reiterated buy/outperform views (Oppenheimer, Cantor Fitzgerald, Jefferies cited) which underpins upside expectations. Read More.
• Positive Sentiment: Wells Fargo published a bullish forecast calling for meaningful price appreciation, adding directional support to sentiment. Read More.
• Positive Sentiment: Recent quarterly results: UTHR reported an EPS beat (EPS above consensus) and revenue growth, which has prompted analyst upward revisions and helps the fundamental story. Read More.
• Neutral Sentiment: Consensus remains a “Moderate Buy” — constructive but not unanimous, keeping expectations elevated yet measured. Read More.
• Neutral Sentiment: Institutional ownership is high (~94% reported), which typically supports liquidity but can limit float-driven volatility. Read More.
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in late March; director Tommy Thompson also trimmed his stake — large officer sales are weighing on sentiment and likely contributed to the stock pullback. CEO sale filing: Read More.; CFO filing: Read More.; coverage: Read More. and Read More.
• Neutral Sentiment: Short-interest data is unclear in recent feeds and does not currently indicate a clear short-squeeze or bearish pressure. Read More.

Analyst Ratings Changes

A number of research firms have commented on UTHR. TD Cowen boosted their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $549.91.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the third quarter valued at about $317,617,000. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter worth about $293,418,000. Invesco Ltd. boosted its stake in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Finally, Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.